Mycobacterium tuberculosis	Mtb
H. proteasome	Human proteasome
MIC	Minimum inhibitory concentration
ACT	Artemisinin-based combination therapies
aaRSAmino	Acyl tRNA synthetase
CQ	Chloroquine
ADME	Absorption, distribution, metabolism, and excretion
SsrA-tagged protein	Caseinolytic-protease-specific degradation protein
RLU	Relative luminescence
WT cell lines	Wild-type cell lines
aaRS	Aminoacyl-tRNA synthetase
ClpP	Caseinolytic proteases
TB	Tuberculosis
Chloromethyl ketones	CMKs
enoyl- reductase	ENR
Enoyl-[acyl-carrier-protein] reductase [NADH]	InhA
Nicotinamide adenine dinucleotide oxidized	NAD+
Nicotinamide adenine dinucleotide reduced	NADH
artemisinin-based combination therapies	ACT
Plasmodium Falciparum	P. Falciparum
Plasmodium falciparum 3D7	CQ-sensitive 3D7
structure−activity relationship studies	SARs
3D7	Chloroquine (CQ) sensitive P. falciparum strain
W2	Chloroquine (CQ) resistant P. falciparum strain
D2d	Chloroquine (CQ) resistant P. falciparum strain
half-life	t1/2
availability	F
WT cells	Wild-type cells